Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress

After the initial approval of the use of tenofovir disoproxil fumarate‐emtricitabine (TDF/FTC) by the US Food and Drug Administration in 2012 for anti‐HIV pre‐exposure prophylaxis (PrEP), uptake was initially limited, but more recent community surveys and expert opinion suggest wider acceptance in some key populations.

[1]  M. Mimiaga,et al.  Differences in PrEP Knowledge and Use in U.S. MSM Users of a Popular Sexual Networking Site Surveyed in August 2013 and January 2014 , 2014 .

[2]  M. Mimiaga,et al.  Project PrEPARE: High Levels of Medication Adherence with Continued Condomless Sex in U.S. Men who Have Sex with Men in an Oral PrEP Adherence Trial , 2014 .

[3]  Megha L Mehrotra,et al.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. , 2014, The Lancet. Infectious diseases.

[4]  R. Street,et al.  Provider Beliefs and Practices About Assessing Sexual Orientation in Two Veterans Health Affairs Hospitals. , 2014, LGBT health.

[5]  K. Mayer,et al.  HIV Providers’ Perceived Barriers and Facilitators to Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative Study , 2014, AIDS and Behavior.

[6]  S. Buchbinder,et al.  Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco , 2014, PLoS medicine.

[7]  P. Polgreen,et al.  Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  David M. Tellalian,et al.  Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. , 2013, AIDS patient care and STDs.

[9]  L. Grohskopf,et al.  Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate Among HIV-Uninfected Men Who Have Sex With Men in the United States , 2013, Journal of acquired immune deficiency syndromes.

[10]  S. Buchbinder,et al.  Correlates of HIV Acquisition in a Cohort of Black Men Who Have Sex with Men in the United States: HIV Prevention Trials Network (HPTN) 061 , 2013, PloS one.

[11]  K. Sepkowitz,et al.  A pill for HIV prevention: déjà vu all over again? , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  S. Hosek,et al.  The Acceptability and Feasibility of an HIV Preexposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men , 2013, Journal of acquired immune deficiency syndromes.

[13]  C. Beyrer,et al.  Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. , 2013, The Lancet. Infectious diseases.

[14]  R. Brookmeyer,et al.  Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. , 2013, The Journal of infectious diseases.

[15]  A. Adimora,et al.  HIV Acquisition Among Women From Selected Areas of the United States , 2013, Annals of Internal Medicine.

[16]  Peter L. Anderson,et al.  Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men , 2012, Science Translational Medicine.

[17]  Douglas J. Taylor,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[18]  John T Brooks,et al.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.

[19]  J. Baeten,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[20]  T. Hart,et al.  Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis , 2012, The Lancet.

[21]  J. Prejean,et al.  Estimated HIV Incidence in the United States, 2006–2009 , 2011, PloS one.

[22]  Sung-Jae Lee,et al.  Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships , 2011, AIDS care.

[23]  K. Mosack,et al.  Physician Awareness of Sexual Orientation and Preventive Health Recommendations to Men Who Have Sex With Men , 2011, Sexually transmitted diseases.

[24]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[25]  W. Jack,et al.  Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial , 2010, The Lancet.

[26]  W. Mcfarland,et al.  Racial Mixing and HIV Risk Among Men Who Have Sex with Men , 2009, AIDS and Behavior.

[27]  M. Otto,et al.  Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. , 2001, Behaviour research and therapy.

[28]  M. B. Bouzas,et al.  Variables that influence HIV-1 cerebrospinal fluid viral load in cryptococcal meningitis: a linear regression analysis , 2009, Journal of the International AIDS Society.